Skip to main content

Paladin acquires outstanding shares of ViRexx


MONTREAL Canadian drug maker Paladin Labs has acquired all outstanding shares of biotech firm ViRexx Medical Corp., Paladin announced Tuesday.

ViRexx, also a Canadian company, develops products using its Chimigen Vaccine Platform, T-ACT Platform for cancer-fighting drugs and the AIT Platform, also for developing cancer drugs. 

Paladin paid $1 million to existing ViRexx creditors, while former ViRexx shareholders could receive a payment of up to $2 million if certain conditions are met before Dec. 31, 2009.

"ViRexx spent over [$24.6 million] in developing its promising, innovative technology," Paladin president and chief executive officer Jonathan Goodman said in a statement. "Unfortunately, ViRexx got caught in this financial storm without a protection of cash."

Amounts in the original Paladin statement were quoted in Canadian dollars.

This ad will auto-close in 10 seconds